Key statistics dashboard for Corbus Pharmaceuticals Holdings, Inc. (CRBP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid typ...
Stock Data
| Price | $7.26 |
| Market Cap | $135M |
| Enterprise Value | $115.4M |
| Beta | 2.79 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.10 |
| Price / Book | 1.36 |
| P/S | 0.00 |
| EV/EBITDA | -1.14 |
| EV/Sales | 0.00 |
| EV/FCF | -1.33 |
| P/FCF | -1.53 |
| Earnings Yield | -72.32% |
| FCF Yield | -64.45% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -87.05% |
| Return on Assets | -80.25% |
| Return on Invested Capital | -100.35% |
| Return on Capital Employed | -101.30% |
Financial Health
| Current Ratio | 5.71 |
| Quick Ratio | 5.71 |
| Cash Ratio | 1.09 |
| Debt / Equity | 0.04 |
| Debt / Assets | 3.36% |
| Net Debt / EBITDA | 0.19 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 5.27 |
| Cash per share | 6.08 |
| FCF per share | -4.47 |
| Tangible Book Value per share | 5.27 |
| Dividend per share | 0.00 |
Related companies: ALEC · APLT · CRDF · ELTX · FBRX · IPHA · MIST
Explore sector: Healthcare · Biotechnology
More sections of CRBP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks